Initiation Archives - Page 264 of 272

1 minute read

Rosenblatt Initiates Coverage On Juniper Networks with Neutral Rating, Announces Price Target of $33

July 13, 5:32 AM

Rosenblatt analyst Mike Genovese initiates coverage on Juniper Networks (NYSE:JNPR) with a Neutral rating and announces Price Target of $33.

JNPR

1 minute read

Stifel Initiates Coverage On SiteOne Landscape Supply with Hold Rating, Announces Price Target of $105

By Benzinga Newsdesk

July 13, 5:30 AM

Stifel analyst W. Andrew Carter initiates coverage on SiteOne Landscape Supply (NYSE:SITE) with a Hold rating and announces Price Target of $105.

SITE

1 minute read

Wells Fargo Initiates Coverage On Dun & Bradstreet Hldgs with Overweight Rating, Announces Price Target of $21

By Benzinga Newsdesk

July 13, 5:28 AM

Wells Fargo analyst Seth Weber initiates coverage on Dun & Bradstreet Hldgs (NYSE:DNB) with a Overweight rating and announces Price Target of $21.

DNB

1 minute read

Wells Fargo Initiates Coverage On Clarivate with Overweight Rating, Announces Price Target of $20

By Benzinga Newsdesk

July 13, 5:26 AM

Wells Fargo analyst Seth Weber initiates coverage on Clarivate (NYSE:CLVT) with a Overweight rating and announces Price Target of $20.

CLVT

1 minute read

Wells Fargo Initiates Coverage On Cintas with Equal-Weight Rating, Announces Price Target of $393

By Benzinga Newsdesk

July 13, 5:24 AM

Wells Fargo analyst Seth Weber initiates coverage on Cintas (NASDAQ:CTAS) with a Equal-Weight rating and announces Price Target of $393.

CTAS

1 minute read

Wells Fargo Initiates Coverage On TransUnion with Equal-Weight Rating, Announces Price Target of $88

By Benzinga Newsdesk

July 13, 5:17 AM

Wells Fargo analyst Seth Weber initiates coverage on TransUnion (NYSE:TRU) with a Equal-Weight rating and announces Price Target of $88.

TRU

2 minute read

UBS Says Braze Stock Is A Buy: What Investors Need To Know

By Adam Eckert

July 12, 2:59 PM

UBS initiated coverage on customer engagement platform Braze Inc (NASDAQ: BRZE) on Monday. What Happened: The analyst firm initiated coverage on Braze with a Buy rating and announced a $53 price target.

BRZE

1 minute read

Avidity Biosciences Or Dyne Therapeutics – Read On Raymond James’ Rating Skew

By Vandana Singh

July 12, 2:54 PM

Raymond James initiated coverage on Avidity Biosciences Inc (NASDAQ:RNA) with a Strong Buy rating and $29 price target (68% upside) and Dyne Therapeutics Inc (NASDAQ:DYN)…

DYN